Purpose: The most critical parameter in the evaluation of the effectiveness of minimally invasive esophagectomy for esophageal squamous cell carcinoma (SCC) is long-term outcome. In this study, patients in whom more than 5 years had elapsed since they had undergone minimally invasive esophagectomy for esophageal SCC were identified, and the 5-year overall survival (OS) rate and 5-year disease-free survival (DFS) rate were evaluated as the long-term outcomes.
Methods: The stage, histology, perioperative complications, recurrence, and survival data were carefully reviewed in 49 patients who underwent minimally invasive esophagectomy for esophageal SCC between January 2008 and January 2010.
Results: Postoperative 30-day complications were observed in 12 (24.5%) patients. There was no postoperative 30-day mortality. Recurrence was observed in 26 patients (53.1%): of these, 9 (18.4%) developed local recurrence and 14 (28.6%) distant metastasis. Three patients (6.1%) had both local and distant metastases. During the study period, there were 22 (44.9%) deaths, of which 20 were due to cancer and 2 were due to other causes. The patient 5-year OS and DFS rates were 58 and 45%, respectively.
Conclusion: Minimally invasive esophagectomy for the treatment of esophageal SCC is as feasible and safe as open esophagectomy in terms of both very long- and short-term outcomes.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Minimally Invasive Glaucoma Surgery and the Distal Aqueous Outflow System: The Final Frontier?
Ophthalmol Glaucoma
January 2025
Baltimore, Maryland.
Robotic-Assisted minimally invasive esophagectomy: Recommendations to textbook outcomes in clinical practice.
J Thorac Cardiovasc Surg
January 2025
Department of Thoracic Surgery I, Key Laboratory of Lung Cancer of Yunnan Province, Yunnan Cancer Hospital, The Third Affiliated Hospital of Kunming Medical University, Cancer Center of Yunnan Province, Kunming, China.
Surgical and Pathological Results Following Neoadjuvant Nivolumab and Platinum-Based Chemotherapy for Locally Advanced Resectable NSCLC: A Multicentre Real-World Series From England.
Clin Lung Cancer
December 2024
Department of Thoracic Surgery, Liverpool Heart and Lung Hospital, Liverpool, UK.
Background: To evaluate the real-world surgical and pathological outcomes following neoadjuvant nivolumab in combination with chemotherapy in a multicentre national cohort of patients.
Methods: Retrospective analysis on consecutive patients treated in three tertiary referral hospitals in UK with neoadjuvant chemotherapy and immunotherapy (nivolumab) for stage II-IIIB nonsmall cell lung cancer (March 2023-May 2024). Surgical and pathological outcomes were assessed.
Deep Serratus Anterior Plane Block for Multimodal Analgesia in Minimally Invasive Mitral Valve Surgery Performed via Right Anterior Mini-Thoracotomy.
J Cardiothorac Vasc Anesth
December 2024
Department of Medical Science, Surgery and Neurosciences, Cardiothoracic and Vascular Anesthesia and Intensive Care Unit, University Hospital of Siena, Siena, Italy. Electronic address:
Objective: This study investigated if the serratus anterior plane block (SAPB) within a multimodal analgesia scheme would reduce acute post-operative pain and intravenous opioid consumption in patients admitted to the intensive care unit after isolated minimally invasive mitral valve surgery.
Design: Retrospective study.
Setting: Patients were admitted to the intensive care unit (ICU) of the University Hospital of Siena (Italy).
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!